Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 231 to 240 of 281 total matches.
Dexmedetomidine Sublingual Film (Igalmi) for Acute Agitation
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
of tolerance and tachyphylaxis, and
with withdrawal symptoms upon discontinuation.
DRUG INTERACTIONS — Use ...
The FDA has approved a sublingual film formulation
of the alpha-2 adrenergic receptor agonist
dexmedetomidine (Igalmi — BioXcel Therapeutics)
for acute treatment of agitation associated with
schizophrenia or bipolar I or II disorder in adults. It is
the first alpha-2 agonist and the only sublingual film
to be approved for this indication. Dexmedetomidine
has been available for many years in an injectable
formulation (Precedex) for sedation in the intensive
care unit and to facilitate procedures such as
mechanical ventilation.
Intravenous Acetaminophen/Ibuprofen (Combogesic IV)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
Acetaminophen and ibuprofen are considered safe
for use by nursing mothers.9,10
DRUG INTERACTIONS ...
The FDA has approved Combogesic IV (Hikma), an IV
solution containing acetaminophen and ibuprofen, to
treat mild to moderate pain (alone) or moderate to
severe pain (in combination with an opioid) in adults
when IV analgesia is considered clinically necessary.
Single-drug IV solutions containing ibuprofen
(Caldolor) and acetaminophen have been available in
the US for years.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):68-9 doi:10.58347/tml.2024.1701c | Show Introduction Hide Introduction
Ublituximab (Briumvi) for Relapsing Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
, systemic absorption of the drug
from breast milk is expected to be minimal.
DRUG INTERACTIONS ...
The FDA has approved the recombinant chimeric
anti-CD20 antibody ublituximab-xiiy (Briumvi – TG Therapeutics) for IV treatment of adults with
relapsing forms of multiple sclerosis (MS), including
clinically isolated syndrome (initial neurological
episode), relapsing-remitting disease, and active
secondary progressive MS (SPMS). Two other anti-CD20 antibodies, IV ocrelizumab (Ocrevus) and SC
ofatumumab (Kesimpta), are also FDA-approved for
these indications.
Med Lett Drugs Ther. 2023 Mar 6;65(1671):36-8 doi:10.58347/tml.2023.1671c | Show Introduction Hide Introduction
A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021 (Issue 1640)
of dihydroergotamine.
DRUG INTERACTIONS — CYP3A4 inhibitors increase
serum concentrations of dihydroergotamine ...
The FDA has approved Trudhesa (Impel Neuropharma),
a new dihydroergotamine nasal spray
product, for acute treatment of migraine with or
without aura in adults. Another dihydroergotamine
nasal spray (Migranal, and generics) has been
available for many years for the same indication.
Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022 (Issue 1643)
proliferative or severe nonproliferative
diabetic retinopathy.
DRUG INTERACTIONS — Pharmacologic ...
Lonapegsomatropin-tcgd (Skytrofa – Ascendis), a long-acting prodrug of recombinant human growth hormone (rhGH), has been approved by the FDA for
once-weekly subcutaneous (SC) treatment of growth
failure due to inadequate secretion of endogenous
growth hormone in children ≥1 year old who weigh
≥11.5 kg. It is the first once-weekly rhGH product to be
approved in the US; other available rhGH formulations
are administered more frequently.
Once-Weekly or Once-Monthly Subcutaneous Buprenorphine (Brixadi) for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
buprenorphine formulation is preferred.
DRUG INTERACTIONS ― Concurrent use of
benzodiazepines or other CNS ...
The FDA has approved a subcutaneously injected,
extended-release formulation of the mu-opioid
receptor partial agonist and kappa-opioid receptor
antagonist buprenorphine (Brixadi – Braeburn)
for once-weekly or once-monthly treatment of
moderate to severe opioid use disorder. Brixadi is
the second subcutaneously injected buprenorphine
formulation to be approved in the US; Sublocade,
which is administered once monthly, was the first.
Buprenorphine is also available for treatment of
opioid use disorder in sublingual formulations with
and without the opioid antagonist...
Med Lett Drugs Ther. 2023 Aug 21;65(1683):133-5 doi:10.58347/tml.2023.1683c | Show Introduction Hide Introduction
Bupivacaine/Meloxicam (Zynrelef) for Postsurgical Pain
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
or
obstetrical paracervical block anesthesia.
DRUG INTERACTIONS — Use of additional local
anesthetics within 96 ...
The FDA has approved a fixed-dose combination
of the amide local anesthetic bupivacaine and
the nonsteroidal anti-inflammatory drug (NSAID)
meloxicam as an extended-release (ER) solution
(Zynrelef – Heron) for single-dose, intraoperative,
soft-tissue or periarticular instillation to provide
postsurgical analgesia for up to 72 hours in adults
undergoing foot and ankle, small-to-medium open
abdominal, or lower extremity total joint arthroplasty
surgical procedures.
Treatment of Clostridioides difficile Infection
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
transmission of SARS-CoV-2.30
DRUG INTERACTIONS — Oral vancomycin and
fidaxomicin are poorly absorbed ...
Clostridioides (formerly Clostridium) difficile infection
(CDI) is the most common infectious cause of
healthcare-associated diarrhea in adults. Guidelines
on management of CDI have recently been updated.
Rozanolixizumab (Rystiggo) for Myasthenia Gravis
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
concentrations in breast milk.
DRUG INTERACTIONS ― Rozanolixizumab can
decrease serum concentrations ...
Rozanolixizumab-noli (Rystiggo – UCB), a neonatal
Fc receptor (FcRn) blocker, has been approved by the
FDA for treatment of generalized myasthenia gravis in
adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.
It is the first drug to be approved for treatment of
generalized myasthenia gravis in patients with anti-MuSK antibodies. Four other biologic drugs – the
FcRn blocker efgartigimod alfa (Vyvgart; Vyvgart
Hytrulo) and the complement inhibitors eculizumab
(Soliris), ravulizumab (Ultomiris), and zilucoplan
(Zilbrysq) – are...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):29-31 doi:10.58347/tml.2024.1696c | Show Introduction Hide Introduction
Cladribine (Mavenclad) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019 (Issue 1577)
with a current malignancy.
DRUG INTERACTIONS — Concurrent use of oral
cladribine and other immunomodulatory ...
The FDA has approved cladribine (Mavenclad – EMD
Serono), a purine antimetabolite, for oral treatment
of adults with relapsing forms of multiple sclerosis
(MS), including relapsing-remitting disease and
active secondary progressive MS (SPMS), who
cannot tolerate or have had an inadequate response
to other drugs indicated for treatment of MS. It is
not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved
for treatment of hairy cell leukemia, has been
used off-label for treatment of MS.